68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)

NACompletedINTERVENTIONAL
Enrollment

169

Participants

Timeline

Start Date

March 1, 2013

Primary Completion Date

December 30, 2015

Study Completion Date

December 5, 2017

Conditions
Neuroendocrine Carcinoma
Interventions
DRUG

68Ga-DOTATATE

68Ga-DOTATATE (3-5 mCi ±25%; 111-185 MBq) is administered as a single intravenous bolus injection in each participant. These injections were performed within 28 days after the Octreoscan.

DIAGNOSTIC_TEST

PET/CT

68Ga-DOTATATE PET images will be acquired 60 ±30 minutes after injection of 68Ga-DOTATATE. 68Ga-DOTATATE PET images were performed within 28 days after the Octreoscan.

DIAGNOSTIC_TEST

111In-pentetreotide OctreoScan

OctreoScan™ was performed after intravenous injection of 111In-pentetreotide, a radiopharmaceutical that binds to somatostatin receptors, if the patient had not undergone such imaging as a standard of care. Subsequent planar and/or SPECT imaging was used to detect somatostatin receptor-positive lesions.

DIAGNOSTIC_TEST

MRI

MRI (Standard of Care)

Trial Locations (1)

77042

Radio- Isotope Therapy of America, Houston

All Listed Sponsors
collaborator

Radiomedix, Inc.

INDUSTRY

collaborator

Excel Diagnostics and Nuclear Oncology Center

OTHER

lead

Radio Isotope Therapy of America

OTHER

NCT01879657 - 68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs) | Biotech Hunter | Biotech Hunter